OPTIMIERTES FAKTOR-VIII-GEN

European patent · EP2956477 · In force

Register entry

Publication number
EP2956477
Application number
EP14751254
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Maintained in amended form
Filed
Feb 14, 2014
Published
Dec 23, 2015
Granted
Nov 18, 2020
Protection ends at the latest
Feb 13, 2034
Next annual fee due
Feb 28, 2027
IPC classes
C07K 14/755 (2006.01)
Priority
US 201361765626 P 15.02.2013
PCT application
PCT/US2014/016441 14.02.2014
PCT publication
WO2014/127215 21.08.2014
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Mar 1, 2026

    Change

    Published in Swissreg on 01.03.2026

  2. Mar 1, 2025

    Change

    Published in Swissreg on 01.03.2025

  3. Mar 1, 2024

    Change

    Published in Swissreg on 01.03.2024

  4. Dec 27, 2023

    Change

    Published in Swissreg on 27.12.2023

  5. Mar 6, 2023

    Change

    Published in Swissreg on 06.03.2023

  6. Nov 17, 2021

    Change

    Published in Swissreg on 17.11.2021

  7. Sep 22, 2021

    Change

    Published in Swissreg on 22.09.2021

  8. Nov 18, 2020

    Granted

    Published in Swissreg on 18.11.2020

Parties

Holder

Bioverativ Therapeutics Inc.

225 Second Avenue, Waltham, MA 02451, US

Inventor

TAN, Siyuan

Lexington, Massachusetts 02421, US

PETERS, Robert, T.

Needham, Massachusetts 02492, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.